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An optically-based injection control system has been developed as a proof-of- 
concept that such is of use for an intravenous drug delivery application. Current clinical 
drug delivery for oncology typically provides for intravenous administration without 
providing awareness of achieved plasma concentration, yet interpatient variability 
produces consequences ranging from toxicity to ineffectual treatments.  We report a 
closed loop injection system integrating a pulse-photoplethysmograph to measure the 
concentration of indocyanine green (ICG) in the circulating blood of a one-compartment 
murine model. A proportional-derivative (PD) controller manages the injection rate in 
real-time. The target function for the controller is the population estimate of the 
pharmacokinetic model developed using Bayesian statistics describing the injection phase 
of a calibration set of 22 injections in mice. The controlled set of 8 injections showed a 
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1.1 Current Medical Treatments 
 
The administration of medication has been simplified to the five rights: right 
medication, right dose, right patient, right time, and right route as a first approximation of 
the appropriate use of drugs [1]. This mantra neglects the variance observed between 
patients and between doses on the same patient in both pharmacokinetics (i.e., drug 
concentration dynamics) and pharmacodynamics (i.e., effects of these concentrations). 
Although the vast majority of drugs that receive Food and Drug Administration (FDA) 
approval have a broad therapeutic window – the range of doses at which a drug is 
effective without unacceptable adverse events – many drugs are available with a narrow 
therapeutic window because the potential benefits outweigh the side effects. For 
example, many chemotherapeutic agents fall into this category [1]. 
For drugs with a narrow therapeutic window, the concentration can be monitored 
over time to be within that window based on an individual patient’s response. These 
adjustments can be made over a longer period of time based on the pharmacodynamics 
(e.g., titrating the dose of warfarin or adjusting the chemotherapy dose based on 
neutrophil counts) or over shorter time scales by adjusting the dose based on the 







during clinical drug administration and the area of therapeutic drug monitoring has arisen 
to regulate the effects of narrow therapeutic index drugs by controlling the 
pharmacokinetics. However, one of the limitations of therapeutic drug monitoring is the 
logistics of measuring blood concentrations at regular intervals and providing timely 
feedback during a single dose.  Clinical therapeutic drug monitoring is generally 
restricted to measuring the pharmacokinetics during a dose and then adjusting subsequent 
doses based on the measured, patient-specific pharmacokinetics [1]. Herein, we 
demonstrate an enhancement of therapeutic drug monitoring in which the drug 
concentration is measured in real-time using optical sensing which allows for controlling 
the concentration of a drug during a dose rather than waiting for the next dose. 
An example of the issues mentioned above may be seen in the in the field of 
anesthetics. It is a well-documented issue that monitoring of the drug delivery and the 
various states of the patient are crucial to maintaining the proper therapeutic and patient 
response. Such issues have seen marked improvement through the application of control 
systems monitoring vitals such as heartrate and mean arterial blood pressure [2]. 
 
1.2 Control Theory in the Medical Field 
 
Control theory has recently begun to branch into the field of medicine through a 
plethora of new and impactful avenues. These are as broad as the application of robotic 
arms to surgical procedures, to the specific implementation of control theory as a manner 
to interface directly with human neurons [3]. Other reports have demonstrated the use of 
proportional-integral-derivative (PID) control [4, 5, 6, 7] with pharmacometrics or fuzzy 
logic theories [3] to manage the dosing of anesthesia or drugs in a clinical setting. It is 




project was intended to adapt to the field of pharmacokinetics. Control in this setting can 
refer to the ability to manage a physiological variable within a desirable range, such as 
heart rate or blood pressure or brain activity, as well as the restriction of a drug 
concentration in vivo within a therapeutic dosing window. A significant limiting factor 
towards implementing control was the availability, or the lack thereof, of an associated 
sensing system to track an instantaneously relevant physiological state. 
 
1.3 Previous Work 
 
Previously this lab implemented a three-wavelength photoplethysmograph (PPG) 
which measures the absorbance (which is related to concentration through Beer’s Law) of 
optically active compounds in circulation, which was employed in this report to provide 
for real-time feedback.  This device was used to measure the concentration of a 
circulating dose of optically absorptive gold nanoshells (a ~100 nm diameter particle) 
used in medical applications such as cancer therapy [8] as well as two drugs: 
amphotericin B [9] and quinine [10]. The probe is physically similar to a pulse oximeter 
and uses a finger or murine tail/leg clip.  The precision of the instrument to provide a 
point estimate of concentration of these nanoparticles, relative to the measurement via 
off-line external blood draws, was reported to be ±20% in the relevant concentration 
ranges. There has also been considerable prior work in this lab pertaining to the 
application of Bayesian modeling to the fields of biomedical technology and medical 
therapy, as can be seen in Magaña, et. al [11]. 
It is also important to provide cases of previous work founded in the field of 
medical controls, as this field only became viable in the last century. Throughout the 




work in the field of medically applied controls. This ranges from applying controls to the 
medical field for monitoring the blood glucose level of a patient in a diabetic coma [12] 
work form the mid 70’s, to the application in cases such as analyzing different potential 
methods of delivering chemotherapy drugs [13], a case similar in idea to this project. In 
the latter project, it is used as an adaptive, closed-loop method to model and control 
patient blood glucose level via state space, with the noted requirement of relevant patient 
data being readily available and viable to collect, it is then a simple matter of minimizing 
a set evaluation function which represents the effect treatment of the patient [12]. In the 
analysis of potential chemotherapy, varying robust optimal controllers were modeled and 
analyzed for their efficacy in treating cancer via chemotherapy, several key nots from this 
project included noting that the less model data that could be obtained, the more drug 
would have to be administered, and recommending the use of 𝐻𝐻∞when an initial dose of 
drug will not have a negative side effect, as doing so will reduce the overall amount of 
drug needed in treatment [13].  Though these are generally theoretical in their treatment 
of the field, they still provide a good background for the work done in this project, as a 
window into what could be expected. 
 
1.4 Project Goals 
 
The primary objective of this thesis is to demonstrate a system that controls the 
shape of the concentration versus time curve of a drug during injection by varying the 
injection rate of the drug in response to real-time concentration measurements to affect a 
reduction on the interpatient variability of blood concentration. Here interpatient 
variability at blood concentration is defined as the amount an individual’s blood 




the infusion rate thus providing the recommended drug concentration.  A patient 
receiving the recommended concentration is more likely to result in an effective 
treatment (by ensuring under-exposure does not occur) with fewer adverse side effects 
(by ensuring over-exposure does not occur). To achieve this objective, a population 
model for the selected drug, ICG, was calibrated a on a BALB/c mouse model; then 
developed a proportional-differential feedback control system (PDCS) that uses real-time 
absorbance measurements from the PPG as feedback; and then quantified the total 
delivered dose and verified we could track a target concentration versus time curve 
through the implementation of the control system on BALC/c mice to ensure it was 
effective in fulfilling its purpose of reducing variance within the therapeutic window. 
 
1.5 Statistical and Computation Methods 
 
It is first necessary in this section to mention the method by which the statistical 
analysis was carried out during this work. For analysis of the data obtained during this 
project Markov Chain Monte-Carlo (MCMC) modeling was utilized via the WinBUGS 
analysis package, run using the R programming language. And it is also prudent before 
discussing MCMC to give a brief introduction into Bayes’ theorem, as it is an integral 
foundation of the MCMC process. 
The focus of this project in the field of pharmacokinetics was based on the 
principles of Bayesian modeling, i.e. the drug concentration within a patient body was the 
given system data utilized in conjunction with a model parameter vector treated as 
random variables by Bayes’ theorem.  Bayes’ theorem as it applies to a system involving 












In (1.1) p represents a probability density; this of course means p(𝜃𝜃) is the prior 
 
distribution of the parameter vector set 𝜃𝜃, that is; the distribution of the parameter set 
without consideration of the model prediction y, which are the values utilized to satisfy 
the model at the given inputs to achieve the value y..  Thus p(y|𝜃𝜃) is used to show how the 
 
data are predicted based on the parameter values and p(𝜃𝜃|y) is the posterior distribution 
for 𝜃𝜃. 
Here, as an aside, it should be noted that the parameter set 𝜃𝜃 represents the 
variables CL, V, and φ0 of the functional form of the model seen in section 3.1 in (3.2), 
and the “inputs” to this model as referred to in this explanation are the time values t 
which correspond to the given y. 
In general to use Bayes’ theorem in a practical way it was necessary to employ an 
algorithmic process, as mentioned above, for the purposes of this project, MCMC was 
selected as this implementation.  In the application of MCMC it does not matter what 
happens with y in p(y|𝜃𝜃), as the model prediction y is the output from the system that is 
being modeled by this process. This means that for the purposes of modeling this system 
using MCMC, the term p(y|𝜃𝜃) is obtuse, as it expects the probability of an unchanging 
data point (no longer model prediction as with Bayes’ theorem), y, to change as the 
values of 𝜃𝜃 change. Therefore, we may replace p(y|𝜃𝜃) with a mean-likelihood estimator 
(MLE) for 𝜃𝜃, L(𝜃𝜃; y); which will tell us the likelihood that our 𝜃𝜃 fits the model, in its’ 
attempt to generate the known data point y. Thus, to restate (1.1) in this way as it applies 





𝑝𝑝(𝜃𝜃|𝑦𝑦)  ∝   𝐿𝐿(𝜃𝜃; 𝑦𝑦)𝑝𝑝(𝜃𝜃) (1-2) 
 
In (1.2) p(𝜃𝜃|y) is proportional to the MLE, L(𝜃𝜃; y), by the probability of 𝜃𝜃, p(𝜃𝜃). 
 
It is this likelihood estimator that is key in determining the value of the posterior 
 
p(𝜃𝜃|y) and therefore the values of the parameter set. Often times to simplify the 
calculations, a conjugate will be used in place of the likelihood estimator L(𝜃𝜃; y). A 
conjugate is a family of functions which describe the distribution of the prior and 
posterior, an example of this would be saying both distributions were Normal, thus using 
a Normal distribution to satisfy the given prior and posterior in (1.2) simplifies the 
calculation greatly [14]. 
It was clear then, from these observations, and prior work in the field of 
pharmacokinetics, that Bayesian statistics was the appropriate method for developing a 
population model for this project as it allowed for rapid prediction model for each test 
mouse [11]. This implementation is what allowed the project to perform under the 
constraints applied, such as number of mice available for data collection, and set equation 
creation. In other words, under the limitations of complexity, a one compartment 
pharmacokinetic model, as was determined necessary for this project, was well suited for 
determination by method of Bayesian statistical analysis. And, as seen from previous 
work in the field of medical controls, verification of the overall effect of this project 
would be idyllically simple, as implementing this model with a controller and analyzing 
the variance would be enough to determine if there had been a sufficient change to the 
therapy given [15]. Thus, the next step would be to implement the Bayesian statistical 





To implement Bayesian statistics, we utilized the open-source WinBUGS 
software package, run through the R programing language. By analyzing the confidence 
interval data for each parameter, and the chi-squared value for the model overall in the 
log files produced by WinBUGS, it was possible to determine if the model configuration 
and generated parameter sets were correct, or that the current model needed to be 
rethought. 
The most important aspect of WinBUGS was its application of Markov Chain 
Monte Carlo integration (MCMC). It is the MCMC which performs the calculations 
necessary to determine the posterior distribution for 𝜃𝜃, p(𝜃𝜃|y), and thus allows the user to 
determine the updated model parameters. MCMC is necessary as often it is not easy, or 
even necessarily possible to determine the correct conjugates required for the integration 
which can be seen in (1.3) [14]. 
 
 
    





Where E[𝜃𝜃|y] is the expectation of the parameter set given the values y, 𝜃𝜃 is the 
 
parameter set, and p(𝜃𝜃|y) is the posterior distribution of the parameter set. As previously 
stated, it is the application of MCMC which in the case of a multi-parameter problem, 
solves the issue of identifying a conjugate prior. This is necessary as with an increase in 
the number of parameters, there is also an increase in the difficulty of determining a 
conjugate probability. Here, a conjugate probability refers to the integral equation which 
is a closed-form expression of the posterior, i.e. an expression which yields the values of 
 
p(𝜃𝜃|y). Therefore, the use of MCMC prevents, or solves, the problem of having to deal 




posterior distribution is of a nonstandard form for an arbitrarily large parameter set, in 
which case the user would have no other suitable option than to apply MCMC [14]. 
The method employed by WinBUGS to implement MCMC is Gibbs sampling. 
 
Gibbs sampling is a special case of the Metropolis-Hastings algorithm which will 
generate the Markov chains by splitting the parametric vector 𝜃𝜃 into sub-vectors which 
 
are each sampled conditionally on the most recent values of all other 𝜃𝜃 parameters [14]. 
This essentially means that each individual model parameter is sampled based on every 
other model parameter at any given time, allowing there to be a more accurate predicted 
value of the sampled parameter. 
The algorithm of Gibbs sampling is as follows [14]: 
 
1. Chose an arbitrary value for each parameter of 𝜃𝜃𝜃. (here super-scripts represent 
 
iteration)  
𝜃𝜃𝜃  = {𝜃𝜃10  , 𝜃𝜃20 … , 𝜃𝜃𝑘𝑘 0} (1-4) 
 
2. Sample new values for each parameter by cycling through the following: 
 
A. Sample a new value for θ1  from the full conditional distribution of θ1 
 
given the most recent values of all other parameters and the data set: 
 
𝜃𝜃11    =  𝑝𝑝(𝜃𝜃1|𝜃𝜃20 … 𝜃𝜃𝑘𝑘 0, 𝑦𝑦) (1-5) 
B. Sample a new value for θ2 from its full conditional distribution 
given the most recent values of all other parameters and the data set: 
𝜃𝜃21  =  𝑝𝑝(𝜃𝜃2|𝜃𝜃11, 𝜃𝜃30   … 𝜃𝜃𝑘𝑘 0, 𝑦𝑦) (1-6) 
Note: θ1 1 is included instead of θ1 0  since it is the most updated version. 
 




This completes one iteration of the Gibbs sampler and generates a new iteration 
of the parameter set 𝜃𝜃 1 
3. Repeat step 2 for many iterations to obtain a sequence of dependent realizations 
 
of the parameter set 𝜃𝜃. 
 
Due to the functionality of Gibbs sampling the full conditional distribution which allows 
the updated parametric information to be obtained can often be reduced to a distribution 
specific random number generational method, thus reducing the overall complexity of the 
entire process considerably [14]. Such an implementation was utilized in this project, 








MATERIALS AND METHODS 
 
2.1 Experimental Setup 
 
All experiments were performed using BALB/c mixed gender mice. The care and 
handling of mice followed the Louisiana Tech University Institutional Animal Care and 
Use Committees protocol. Prior to injection, each mouse was kept under specific 
temperature control (35-39°C) to facilitate intravenous cannulation and to maintain 
consistency with drug delivery protocols designed to promote profusion. Isoflurane 
inhalation (3% for induction and 2% for maintenance) anesthesia was used to immobilize 
a mouse during the injections; this aided in the collection of data [5]. 
 
2.2 Injections of ICG in Mice 
 
A fresh ICG solution was prepared each day with a target concentration of 156 
mg/mL which, according to Beer’s Law (A = εcd), has an absorbance of 300; the actual 
absorbance of ICG used varied from 197 absorbance to 318 absorbance. Stability of the 
solution at this high concentration necessitated the use of dimethyl sulfoxide (DMSO) 
(10% by volume) and spectrographic analysis to ensure that the peak at 780 nm was 
dominant in the stock solution [15]. 
ICG injections were given with the intent to reach one of three pre-specified 






absorbance), and large (3.75 absorbance). Each mouse was kept at approximately 36°C 
for the duration of the experiment in the presence of a space heating fan, and placed on a 
heating pad set to that temperature. The injections were carried out intravenously via tail 
vein using a custom catheter system fashioned from a 28 gauge needle tip and 2-french 
tubing. The method of injection was through a syringe pump (New Era Pump Systems, 
Inc. Farmingdale, NY. Model # NE-1010) which was programmed to inject the provided 
ICG solution at an initial rate of 15 µL/min. During the course of all injections, the data 
was collected by the PPG data probe, placed near the base of the mouse’s tail. 
 
2.3 The Photoplethysmograph 
 
The PPG is a non-invasive optical monitoring device that can detect an optically 
active compound in the blood stream by measuring the optical extinction at three 
different wavelengths of light [16]. The PPG consists of an optical probe, analog signal 
modification circuitry and a LabVIEW DAQ which feeds all the received data into the 
created LabVIEW program for processing, monitoring, and cataloguing. Given the 
optical similarity of ICG dye to the nanoparticles for which the system was initially 
designed, the probe was implemented unchanged using optical extinction measurements 
at 660 nm, 805 nm, and 940 nm. This probe detects the pulsatile blood signal in a tissue 
mass and calculates the concentration of ICG according to AC805/DC [9]. 
When using the PPG, a strict inclusion criteria was maintained on all collected 
data. A data point was created by the system by averaging data collected over 5 seconds. 
The criteria for retaining each data point was that it had a standard deviation of less than 




wavelengths each be within 20% of the computed mean heart rate, and that the voltage 
peak-to-peak of the AC portion be greater than 1.5 mV [11]. 
 
2.4 Bayesian Analysis 
 
In order to implement the feedback control system with the PPG, it was necessary 
to first create the population model. The selected method for creating the population 
model for this study was Bayesian statistics. Bayesian statistics is the application of 
previously collected data to statistical models as a method of enhancing and adapting the 
accuracy of the models. This can be rephrased in more technical terms to mean that 
Bayesian statistics allows the user to assume a certain statistical distribution exists for a 
given random variable, and then update that distribution with observed knowledge, i.e. 
adapt and update the model with the new information [14].  In doing so, it lends itself 
well to the method of creating population models, in which case the model parameters 
would generally be taken to be random variables. It should be noted that this is contrary 
to the frequentist statistical analysis in which the data are considered to be random 
variables and the model parameters are considered to be unknown set values [14]. This 
means that by applying Bayesian statistics to model creation by collecting new 
information from individuals of a population the model may be updated for a better fit to 
the population. 
The version of WinBUGS used in this study was 1.4.3. This was implemented 
with R version 3.1.2. The R packages used in this implementation were R2WinBUGS, 
coda, lattice, and MASS. To determine the fit of the model to a given parameter set the 
chi squared value was observed, this represents the variance of the variance of the model 




squared value it was possible to determine if the model was an over-fit, as was discovered 








PHARMACOKINETIC MODEL IDENTIFICATION 
 
3.1 The Population Pharmacokinetic Model 
 
Pharmacokinetics is the study of how therapeutic agents are changed by a body or 
system, population pharmacokinetics is the application of this study with the intent of 
generalizing the outcome a population of organisms will have on a specific therapeutic 
agent. Thus population pharmacokinetics was ideal for implementing a set equation for 
the controller used in this study.  The population pharmacokinetic model was identified 
by comparing the absorbance versus time data and pharmacokinetic model predictions 
using the WinBUGS software. The covariate free one compartment model structure 
selected for use in this study was determined by observing the deviance information 
criterion of different pharmacokinetic models. The following model components were 
evaluated: inter-mouse variability and inter-trial variability on clearance (the rate at 
which a body removes a therapeutic agent) and volume of distribution (the effective 
volume which a given therapeutic agent may reach within a body); additive, proportional, 
and combined residual error models; and covariate effects of heartrate, O2  (Oxygen) 
level, and mouse weight on clearance and volume of distribution. A non-informative 









parameters. Inverse gamma distributions were used for the precision of normally 
distributed error [11]. 
The one compartment model, given by (3.1) or (3.2), provided an excellent fit to 
the available data based on the measured absorbance. The concentration of the 
therapeutic agent in the mouse bloodstream was available in the form of experimental 
data from the PPG [11].  
 















A(𝑡𝑡) = [ ] 𝑒𝑒   𝑉𝑉    + 
𝐶𝐶𝐿𝐿 + 𝜑𝜑0 (3-2) 𝐶𝐶𝐿𝐿 
 
In equations (3.1) and (3.2) A(t) is the absorbance (as an analogue for 
concentration), CL is the clearance rate, V is the volume of distribution, φ0 represents the 
absorbance shift from baseline due to PPG system noise, RATE(t) is the injection rate 
over time, and t is time. These variables correspond to the basic theory in chemical 
engineering of the extinction of a one compartment system with a given input 
concentration of an external solution. As such they correspond to the same concepts as 
within the pharmacokinetic model, where clearance rate is the rate of flow of the base 
fluid of the compartmental system, volume of distribution is the volume which the input 
solution may theoretically extend to within the compartment, or theoretically the volume 
of the compartment itself, and rate corresponds to the inflow rate of the input solution. It 
is interesting to note how similar this system ideology is to the analog in electrical 
engineering involving a single pole filter. 
An ICG pharmacokinetic model for BALB/c mice was identified based on 




into three injection size categories: small (7 injections), medium (9 injections), and large 
(6 injections) using 8 BALB\c mice (see Figure 3-1). 
 
 
Figure 3-1: Flow chart describing distribution of mice within experimentation 
parameters. 
 
Once the final population pharmacokinetic model was identified, we used the 
posterior distribution of parameters from WinBUGS as the population model parameters 
defined above. In other words, the values of CL, V, and φ0 were determined through 
WinBUGS in the manner described in section 1.5 wherein they constituted the 
components of a parameter vector, 𝜃𝜃, as described in equation (1.4). It was these 
parameters that are applied to the pharmacometric model set equation (3.2) for 







CHAPTER  4 
CONTROL SYSTEM AND TUNING 
 
4.1 Selected Control System 
 
In this study a form of PID controller was selected for use with the system. This 
was because of the overall ease of implementing a PID style controller. A PID controller 
needs only to be properly tuned and then provided the error signal produced by the 
system which it is controlling. Had this study used another form of control, it would have 
been necessary to design the controller from the ground up, which can be a tenuous 
process in itself. The most important aspect of designing a controller is verifying its 
stability, which is systematically possible, but can become extremely difficult depending 
on the required components of the controller.  Overall to avoid such complications, as 
this study more focused on a proof-of-concept approach to the application of control 
theory to a medical treatment, a form of PID controller was selected for use with this 
project. 
A proportional-derivative (PD) control system was used to control the error 
between the pharmacokinetic model predictions (the set equation) and the current 
concentration measurement (system signal). This PD system is a reduction of a 
proportional-integral-derivative (PID) control design. This reduction from PID to PD 







to go to zero. This is due to the fact that the integral term sums the error for all of process 
run-time [17]. Therefore, as this was a medical system designed with undershooting the 
set equation in mind it was beneficial to avoid using an integral term in the controller. 
 
4.2 Control System Tuning 
 
Although data points from the system were digital, not analog, the PD control 
system worked in much the same manner as would an analog PD control system: it 
numerically differentiated the error signal rather than using the analog derivative. The 
PPG collected data once every 5 seconds so the signal was discrete rather than 
continuous. This influenced the controller because the error signal was discrete as well. 
We used a continuous time solution to the differential equation for the set equation and 
then input the current time index of the received PPG data from the injection. This 
avoided any discrepancy between the analog-discrete setup we created because it allowed 
the analog differential equation to be used at the discrete points of data. As seen in the 
(4.1), the system error, e(t), is calculated and used by the PD error equation. 





The values kp = 124.56 and kd = 48.91 were obtained using the Zeigler-Nichols 
tuning rule, where u(t) is the controller [18]. The controller was operated based on a 
bang-bang principle. This means when the system was operating within its bounded 
margin of error, i.e. the current value of absorbance (OD) was within 30 % of the set 
equation A(t) (3.2) based on the value of u(t), no action was taken by the adjustment 
equation, and conversely when the system was operating outside this bound based on 







𝑅𝑅(𝑡𝑡  + 1/15) − 𝛼𝛼 
=  15 + ( ) ∗ 4000 (4-2) 
𝐶𝐶 
 
In (4.2) RATEi+1 represents the next value of the injection rate in microliters per 
minute, 15 represents the base injection rate which the model assumes, i.e. 15 microliters 
per minute, A(t) is the absorbance equation seen in (3.2), αi represents the actual value of 
absorbance last measured by the PPG at time ti, the +1/15 term is used to calculated the 
PPG measurement at the next discrete time point, and C is the measured concentration of 
the stock solution of ICG being used in the current injection. The 4000 term is used to 
adjust the delta y calculation from absorbance to units of microliters per minute. 
Traditionally a controller is implemented in such a way as to directly influence 
the system, not in following the method of bang-bang; equation (4.3) describes this 
operational methodology as it applies to this project. 






In (4.3) RATEi represents the current value of the injection rate in microliters per minute, 
RATEi-1 represents the last value of the injection rate in microliters per minute, and u(t) is 
the controller equation as seen in (4.1). 
An important concern we held in developing a control system for use as a 
therapeutic device was the potential danger of an erratic or poorly tuned system to the 
patient. In the event the controller were to over predict and inject more than required of a 
therapeutic agent, the patient would be at risk of toxicity. Therefore, we developed the 
controller with an intentional negative bias to ensure we were below the population 
pharmacokinetic curve and reducing the risk of toxicity by turning off the pump if the 




adjustment to the desired model value at the next time interval of measurement, and in 
essence represents the classical method of Euler a la yi+1 = yi + dy. This was chosen as the 
method of updating the RATE variable as the system operation time is in the range of 
seconds.  Such a rapid response time allowed the use of this simple method, and due to 
the fact that this project was mainly a proof of concept a simpler method was desirable 
for the practicality of implementation. 
 
4.3 Control Software 
 
The control software was the primary component for enacting the objective of this 
project: controlling the drug concentration with time. The control software was written in 
the Python programing language, version 3.3.0, and - implementing the serial, numpy, 
matplotlib, tkinter, time, os, and math libraries - it controls the ICG injections based on 
the real time absorbance measurements from the PPG. The set equation implemented for 
the PD control system was the identified Bayesian population pharmacokinetic model. 
The system enacted its changes through use of serial communication with the injection 
pump, calculating a new injection rate based on the current system error. Displaying all 
available mouse data (heart rate, O2, absorbance, injection rate, and total volume 
injected), and allowing for emergency system stop, the software was self-contained; 
given a concentration of ICG and valid injection endpoint, the system would run the 
injection to completion, auto-stop the pump, and then continue monitoring after injection. 
To validate that the control system could follow a desired concentration versus 
time profile, the tuned system with pharmacokinetic model parameters and the PD 
control values were set within the software. This was then applied to a total of 8 




performed with 3 in the small, 3 in the medium, and 2 in the large target absorbance 
group. The data collected from these injections was used to determine if control based 
medication was a valid option in future treatments. 
 
4.4 Analysis of Controller 
 
The viability of the controller was demonstrated using the error between the 
measured absorbance of each data point and the corresponding population 
pharmacokinetic model prediction.  The primary outcome was the reduction in variance 











5.1 Data Inclusion Criteria 
 
The PPG absorbance measurements were verified using the standard data metric 
for the device; any collected data from experiments was held to this metric to ensure 
reduced variability. An example of this metric for an uncontrolled injection is in the test 
output in Figure 5-1. These inclusion criteria are the following: average together the 
three vales for heartrate obtained from each of the three wavelengths (660 nm, 805 nm, 
and 940 nm), and ensure an individual data point has its heartrate values within 20% of 
this mean heartrate, if not discard the data point. Next, measure the AC signal amplitude 
of each heartrate signal, and ensure they are between 1 and 100 mV. The final step in 
verifying the data is to ensure that no repeating data points are retained, as the PPG 
collects a new data point every 5 s, but records data every second, thus, the median data 
point in a 5 s collection group is selected and retained, this happens only if the others in 
its group of 5 s were not rejected following the criteria above, else that data point is also 
rejected.  The applied inclusion criteria was developed by a previous project from this 
lab, when the PPG was developed for use with gold nanoparticles [16] (see The 
















Figure 5-1: (Left) Example photoplethysmograph output of absorbance vs. time from 
mouse injection for an uncontrolled injection. (Right) Corresponding heartrate data from 




5.2 Population Pharmacokinetic Model 
 
A single compartment model provided an accurate and unbiased fit to the 
calibration data (22 injections performed on 8 mice at 3 maximum absorbance levels). 
This was verified following analysis of the chi-squared value from the output file, as 
mentioned in (2.4). There were no significant covariate effects on any of the model 












The half-life from the calibration injections (1.89 min) agrees with a previously 
published report (2-4 min) [19]. 
 
5.3 Analysis of Controlled Injections 
 
The primary outcome is that there was a 74.8% reduction in variance of the 
controlled group Figure 5-2. As can be seen, not only was the controlled group less 
varied on an individual basis of the injections, but the overall spread of the injection 
around the average was smaller as well. This data definitively displays the reduced 









Figure 5-2: (Left) model comparison error of 22 injections from the controlled group 
represented as a standard box plot about the average (solid line) approximately 0. (Right) model 
comparison error of 8 injections from the controlled group as a standard box plot about the 




A demonstration of the controller in action can be seen in Figure 5-3. The system 
is corrected by increasing the injection rate when the measured concentration was below 









Figure 5-3: (Left) Example absorbance with time with injection control. (Right) 
Corresponding PD error and calculated injection-phase rate change. The dashed line is an 
asymptote of error (averaged) and solid line on left is the population pharmacokinetic model. 
 
 
With the controller in place, we had a variance in the clearance rate comparable to 
that seen in the clearance rates and cardiac output metrics obtained in clinical studies 
employing ICG, using pulse dye densitometry [18, 19]. As seen in Figure 5-4 the control 
group injections are displayed in comparison to the population pharmacokinetic model to 
represent this. 
Because the goal of this project was the reduction in variability of injections of a 
therapeutic agent, we also analyzed the delivered dosage generated by the controller for 
each injection Table 5-2. While the control system may be given a certain termination 
point in time or absorbance, it was not calculating or using the area under the curve, or 
AUC, as is standard in many pharmacological studies. This is due to the systems 
feedback mechanism. Data collected by the PPG was optical absorbance, and therefore 
keeping the system simple and operating on this variable was ideal as this was only a 







Table 5-2: Comparison between expected dose (Exp) and achieved dose (Inj) 










Figure 5-4: Injections from Controlled Data Set (dots) with target model (solid line) and 
95% credible interval (dashed line), absorbance vs. time. Figures (a) – (c) have a final 
absorbance target of 2.25, figures (d) – (f) have a final absorbance target of 3.00, and 












A population pharmacokinetic model was developed for the therapeutic agent 
ICG to study the feasibility of using a closed-loop PD control system for tracking a 
desired concentration profile during intravenous administration of drugs. We found that 
closed-loop control of ICG reduces variance from the target injection concentration 
profile by 74.8%. 
 
6.2 Controller Advantages 
 
There are several advantages to closed-loop control of injections for tracking a 
desired concentration profile. These are primarily due to the applied control system’s 
application of system error when calculating the next move to make. For example, our 
approach has the potential to reduce acute toxicity by ensuring that the actual 
concentration is below the population pharmacokinetic model. Another example may be 
seen in the application of closed-loop control to a highly sensitive therapy. Take for 
example one which needs to be maintained in a tight therapeutic window for an extended 
period. Keeping the patient within this window is a considerably less difficult task as the 
system can be designed to maintain the window rigorously with the application of 






closed-loop control system is perhaps the most poignant caveat of control and automation 
systems in general. Control systems allow the designer to choose the operation and 
response time as well as the method and number of system reactions to a specific 
stimulus as relayed in the system error. Meaning, it is up to the designer in what way and 
how fast any form of system error is processed. Thus, the controller provides a more 
dynamic and robust platform upon which to expand any system. This cannot be 
accomplished without system feedback, and therefore cannot occur without the closed- 
loop. 
 
6.3 Pharmacokinetic Observations 
 
In going from a target absorbance of 2.25 (Inj #1) to an absorbance of 3.75 (Inj 
 
#8) required 5 times the dose. Injection #1 appears to require a below average dose to 
achieve the desired concentration so the administration of the expected dose may lead to 
over-dose. On the other hand, Injection #8 required an above average dose to achieve the 
desired concentration so administering the expected dose may not be effective. 
 
6.4 Controller Error Response 
 
The best case of this can be seen in the overall error response of the Controlled 
group, where the error is centered below the marginal average of zero. This is due to the 
system design. As previously mentioned considered the potential threat of therapeutic 
toxicity, we therefore implemented a negative bias as a precautionary measure.  While 
this increases system response time, this has two benefits; it allows our system to run 
longer and therefore approach the asymptotic PD error margin of zero, as well as reduces 




6.5 General Outcome 
 
Beyond this initial impact in reducing the variability of patient treatment, this 
study is an important step in the direction of fully-automated therapeutic systems. We 
demonstrate that the idea of self-sustained and self-controlled treatment systems is not 
only practical, but closer than other current work would seem to suggest. Overall, our 
study shows that interpatient variability need not influence the outcome of a clinical 
study, and by the same token, personalized medicine is in the near future. 
 
6.6 Project Drawbacks 
 
It should be noted that this study did not include the pharmacodynamics when 
considering our control system. This is reflected primarily in the choice of our style of 
control; i.e. a PD control system. Classically PID and all related modes of control are 
utilized in situations in which there are a plethora of unknown and or unmeasurable 
variables. The general idea behind a PID being to tune the error signal to a prespecified 
series of results in order to achieve the desired system convergence. In doing so, we 
focused entirely on meeting the goal of reduction of inter-patient variability and left all 
other system variation up to the control system. Thus, having designed our system 
around these aspects of the pharmacokinetics, no considerations had been made for the 
effect which the drug was having on the patients. 
The main limitation is the system’s undershooting of the population 
pharmacokinetic curve, though this is a measure to protect the patient from toxicity, (a 
potentially realistic concern in our overstepping of pharmacodynamics). In the future, a 
more finely calibrated control system, made with a more sensitive PPG, would not have 




absorbance as the target and general pharmacokinetic model standard in our study is not 
the clinical tradition. 
Although this project focused on the use of optically-based controller feedback, 
the system need not have any specific type of sensory feedback. In future work, an 
exploration into other clinical metrics such as glucose, neurotransmitters, and hormone 










7.1 Future Work 
 
Controller based medical therapy is a new and developing field. As shown in our 
work it holds promise in reducing inter-patient variability. The future application of 
controllers to the many forms of medical treatment is the key to resolving the current 
issues held in the medical field which limit treatments based on small margins of 
population effectivity and will allow physicians to be more certain of the reliability of 
medical treatment overall. Such future works in this field might include the creation of a 
more compact version of the device utilized within this project, such that it might fit on a 
patient arm, containing all components of the described system within a smaller, closed- 
form casing, perhaps one that is 3D-printed to increase feasibility, reduce cost, and 
increase the device fit on an individual patient. Such a device might have a touch screen 
with a variety of options of therapeutic windows and/or treatment-session 
goals/outcomes, and would likely include a peripheral device worn at another location on 
the patient, such as the opposing wrist/appendage, to gain a more accurate measure of the 
administered drugs profusion. This hypothetical device need not focus solely on the 
application of optically-based feedback, but might also take measurements in similar 







hypothetical device would also likely not need to apply an undershoot or bias as was 
utilized in this project, and thus could potentially very tightly control the administration 
of its drug allowing previously toxic drugs to be safely administered. As can be seen from 
even one such theorized device, the future of control based medication holds potential as 
a means to broaden the availability of medical treatments to the global populous in a way 









CALIBRATION DATA MODELS AND VALIDATION DATA 
 
The data used to develop the pharmacokinetic model, the calibration set, was 
analyzed on an individual basis. Each injection profile was modeled with a one- 
compartment pharmacokinetic model and in conjunction with properly determining the 
covariate effects which were potentially present, the heartrate of each mouse was also 
collected and graphed. This data is presented here, in Appendix A. Data was also 
collected during the validation experiments, for the purpose of future analysis and has 
also been included here, in Appendix A. A general note on the nomenclature used, M#I# 
in the below image captions represents which mouse number from a set, and which 





























Figure A-1: (Top) Injection profile M1I1 (dots) with model (red line) and (bottom) heart 






Figure A-2: (Top) Injection profile M1I2 (dots) with model (red line) and (bottom) heart 






Figure A-3: (Top) Injection profile M2I1 (dots) with model (red line) and (bottom) heart 






Figure A-4: (Top) Injection profile M2I2 (dots) with model (red line) and (bottom) heart 







Figure A-5: (Top) Injection profile M2I3 (dots) with model (red line) and (bottom) heart 






Figure A-6: (Top) Injection profile M3I1 (dots) with model (red line) and (bottom) heart 






Figure A-7: (Top) Injection profile M3I2 (dots) with model (red line) and (bottom) heart 






Figure A-8: (Top) Injection profile M3I3 (dots) with model (red line) and (bottom) heart 






Figure A-9: (Top) Injection profile M3I4 (dots) with model (red line) and (bottom) heart 






Figure A-10: (Top) Injection profile M4I1 (dots) with model (red line) and (bottom) 






Figure A-11: (Top) Injection profile M5I1 (dots) with model (red line) and (bottom) 






Figure A-12: (Top) Injection profile M5I2 (dots) with model (red line) and (bottom) 






Figure A-13: (Top) Injection profile M5I3 (dots) with model (red line) and (bottom) 






Figure A-14: (Top) Injection profile M5I4 (dots) with model (red line) and (bottom) 






Figure A-15: (Top) Injection profile M6I1 (dots) with model (red line) and (bottom) 






Figure A-16: (Top) Injection profile M6I2 (dots) with model (red line) and (bottom) 






Figure A-17: (Top) Injection profile M6I3 (dots) with model (red line) and (bottom) 






Figure A-18: (Top) Injection profile M7I1 (dots) with model (red line) and (bottom) 






Figure A-19: (Top) Injection profile M8I1 (dots) with model (red line) and (bottom) 






Figure A-20: (Top) Injection profile M8I2 (dots) with model (red line) and (bottom) 






Figure A-21: (Top) Injection profile M8I3 (dots) with model (red line) and (bottom) 






Figure A-22: (Top) Injection profile M8I4 (dots) with model (red line) and (bottom) 






Figure A-23: Validation Injection profile M1I1, (dots) with population model (red line). 
 






Figure A-25: Validation Injection profile M1I3 (dots) with population model (red line). 
 






Figure A-27: Validation Injection profile M2I1 (dots) with population model (red line). 
 






Figure A-29: Validation Injection profile M2I3 (dots) with population model (red line). 









CODE FOR SOFTWARE & STATISICAL ANALYSIS 
 
During the course of this study there were two main programming languages 
utilized for the development of the software and the statistical analysis of the data. The 
language selected for the creation of the software was Python v3.3. The external modules 
utilized in the creation of the software were: math, matplotlib, tkinter, os, serial, and time. 
A process flow diagram, as well as the core code for the software are included here, in 
Appendix B. 
The language chosen for statistical analysis was WinBUGS v.1.4.3. It utilized the 
R programming language v.3.1.2 as a container language for processing and ease. The R 
code which was utilized to by WinBUGS is included here, in Appendix B. The included 




























Figure B-31: Process flow diagram for Python Control Software. 
 
Below is the core code from the Python program which carried out the process flow 
described in Figure B-1. The red text preceded by a pound-sign are comments, the green 
text are key words in the python language syntax. The blue text is the name of a defined 
function.  The orange text are text strings.  The purple text denotes functions and 
variables that are properties of the overall class structure. An ellipsis (…) implies the line 
continues as a truncated line, one line down from the ellipsis. 
def execute(self): 
# If an Injection has not begun 
if not self.on: 
# Activate Injection 
self.on = 1 
self.stop_on = 0 
self.state = 0 
self.menuactive(0) 
# Check if user wants to clear data 
if self.clearvar.get() == 0: 
if self.restart: 
self.query_clear = M.askyesno(message = 'Would you like to clear all... 





# If we are restarting an injection, and the users asks, clear all data 












self.pump_running = 1 
except SerialException: 
self.wind("Serial Communication Error!") 
self.breaker = 0 
 




# Create a Zero-null time index 
self.initial_x = float(self.current_line[9]) 
 
# Measure time positively from the Zero-null index 
self.x[0] = float(self.current_line[9])-self.initial_x 
# Get the OD at the current time index 
self.y[0] = float(self.current_line[17]) 
# Set the PID setpoint to the model value at the current time index 
self.PID.setPoint(self.injection_model(self.x[0])) 
# Calculate the PID error at the current time index 
self.error = self.PID.update(self.y[0]) 
# Pass the current OD to a past-point container 
self.past_od = self.current_line[17] 
# Update the Graph 
self.update_points() 
# Force GUI update in case of any issues. 
self.update() 
 
# Numerical Integration to find Injected Volume 
self.injected_volume += self.rate_calc_var*0.0666666667 
self.injection_var.set(str(round(self.injected_volume, 4))+' uL') 
 
# Time-out variable 
self.borrow_iterator = time() 
 
# Loop the above (without the definition of a Zero-null index) 
while(self.breaker): 




if self.current_line[17] != self.past_od: 
self.x[0] = float(self.current_line[9])-self.initial_x 




self.error = self.PID.update(self.y[0]) 
self.PID_err_variable.set(str(round(self.error, 4))) 
 
if self.state == 0: 




self.injected_volume += self.rate_calc_var*0.0666666667 






if abs(self.error) >= self.E_max: 
self.pump_control() 
 








# Warn the user of a time-out from PPG connection and ask what they'd like 
to do. 
if time()-self.borrow_iterator >= 4: 
if self.pump_running == 1: 
self.query = M.askyesno(message = 'A communication timeout has... 






self.wind('A communication timeout has occurred!\nAssumption: Process... 
Complete') 
self.menuactive(1) 




# If inital run failed, warn user, only possible case would be a missing file 
from the PPG. 
except FileNotFoundError: 
self.wind('File not Found!') 
self.menuactive(1) 
 
# Ijection is done, tell the system it's not running. 
self.on = 0 
 





Below is the R utilized for the Bayesian statistical analysis from this project. 
 
rm(list = ls()) 
 
model_name <- "1_comp_model_analysis" 
 
######################################################################### 
# set directories and load packages ##################################### 
######################################################################### 
 
working_directory <- "C:/Users/Trey/Desktop/Research Data/WinBUGS Analysis" 
#/WinBUGS Analysis" 
WinBUGS_directory <- "C:/Users/Trey/Documents/Winbugs" 















# data and variables #################################################### 
######################################################################### 
data <- read.csv(file.path(working_directory,"WinBUGS Data.csv"), header=TRUE) 
bugsdata <- list( 
N_observations = nrow(data), 
#N_mice = max(data_bolus$MOUSE), 
N_trials = max(data$TRIAL), 
#MOUSE = data$M, 
#GROUP = data_bolus$GROUP, 
TRIAL = data$TRIAL, 
INJ = data$I, 
TIME = data$TIME, 
OD = data$OD,#as.numeric(data$DV), 
TAU = data$TAU, 
CONC = data$CONC, 
HR = data$HRS 
#DOSE = data$DOSE 
 
#AMT = data_bolus$AMT 
# RATE = data_bolus$RATE 
# DOSE = data_bolus$DOSE, 
# WT = data_bolus$WT 
) 
 
bugsinit <- function() { 
rnorm.trunc <- function(n,mean=0,sd=1,lower=-Inf,upper=Inf) { 
qnorm.trunc(runif(n),mean,sd,lower,upper) 
} 





CL_0 = rnorm.trunc(1, 1.097, 0.1, lower=0), 
CL_precision = rnorm.trunc(1, 6.016, 0.6, lower=0), 
V_0 = rnorm.trunc(1, 3.016, 0.3, lower=0), 
V_precision = rnorm.trunc(1, 1.796, 0.1, lower=0), 
phi_s_0 = rnorm(1, 0.662, 0.06), 
phi_s_precision = rnorm.trunc(1, 17.466, 01.7, lower=0), 
X_precision = rnorm.trunc(1, 1.392, 0.1, lower=0) 
#beta = rnorm(1, 0 , 1) 
#beta_l = rnorm(1, 0, 0.001), 
#beta_m = rnorm(1, 0, 0.001), 
#beta_s = rnorm(1, 0, 0.001) 
 
#beta_group_CL_A = rnorm(1, 0, 0.1), 
#beta_group_CL_B = rnorm(1, 0, 0.1), 
#beta_group_CL_D = rnorm(1, 0, 0.1), 
#beta_injection_CL = rnorm(1, 0, 0.1), 
#beta_group_V_A = rnorm(1, 0, 0.1), 





#beta_group_V_D = rnorm(1, 0, 0.1), 
#beta_injection_V = rnorm(1, 0, 0.1), 
#beta_preinjection_V = rnorm(1, 0, 0.1), 
#beta_preinjection_CL = rnorm(1, 0, 0.1), 




parametersToPlot <- c("CL_0", "V_0", "phi_s_0", "X_sigma", "CL_sigma", 
"V_sigma", "phi_s_sigma", "CL_trial", "V_trial", "phi_s_trial") 
# "beta_preinjection_CL", "beta_group_V_A", "beta_group_V_B", 
"beta_group_V_D", "beta_group_CL_A", "beta_group_CL_B", "beta_group_CL_D", 
"beta_injection_CL", "CL_mouse", "V_mouse", "CL_sigma_mouse", "V_sigma_mouse" 
 
otherRVs <- c() 
 
parameters <- c(parametersToPlot, otherRVs) 
parametersToPlot <- c("deviance", parametersToPlot) 
 
######################################################################### 
# run WinBUGS ########################################################### 
######################################################################### 
 
#n.chains <- 2 
#n.iter <- 2000 
#n.burnin <- 1000 
#n.thin <- 1 
 
n.chains <- 5 
n.iter <- 20000 
n.burnin <- 10000 
n.thin <- 5 
 
bugs.fit <- bugs( 
data = bugsdata, 
inits = bugsinit, 
parameters.to.save = parameters, 
model.file = file.path(working_directory, paste(model_name, ".txt", 
sep="")), 
n.chains = n.chains, 
n.iter = n.iter, 
n.burnin = n.burnin, 
n.thin = n.thin, 
clearWD = FALSE, 
debug = FALSE, 
bugs.directory = WinBUGS_directory, 
working.directory = getwd() 
) 
WinBUGS_output = bugs.fit$sims.array 
posterior = array(as.vector(WinBUGS_output), 
dim=c(prod(dim(WinBUGS_output)[1:2]), dim(WinBUGS_output)[3]), 
dimnames=list(NULL,dimnames(WinBUGS_output)[[3]])) 
posterior <- subset(posterior, select=c(-deviance)) 
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